Vanguard Global Advisers
IRD

Vanguard Global Advisers’s Opus Genetics IRD Stock Holding History

Vanguard Global Advisers’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.9K Sell
14,342
-7,883
-35% -$36.8K ﹤0.01% 3012
2026
Q1 		$101K Buy
+22,225
New +$76.9K ﹤0.01% 2722

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's IRD Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Opus Genetics (IRD) stake by 35% in Q2 2026, selling an estimated $36.8K and leaving 14,342 shares worth $58.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3012.

Vanguard Global Advisers first reported a position in IRD in Q1 2026 and has held it in 2 quarters since. The position peaked at $101K in Q1 2026. 100 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Vanguard Global Advisers held 14,342 shares of Opus Genetics worth $58.9K as of Q2 2026.
  • Vanguard Global Advisers sold 7,883 Opus Genetics shares in Q2 2026, an estimated $36.8K.
  • Opus Genetics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3012 holding.
  • Vanguard Global Advisers first reported a position in Opus Genetics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Opus Genetics position peaked at $101K in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.